Trials / Completed
CompletedNCT00207090
Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- R-Pharm · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ixabepilone | ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression |
| DRUG | Rifampin | rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2 |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2005-09-21
- Last updated
- 2020-11-02
- Results posted
- 2010-10-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00207090. Inclusion in this directory is not an endorsement.